我们选取了149家港股医药上市公司,2024年收入总额17845亿元(+1.81%),归母净利润792亿元(+49.3%),扣非归母净利润584亿元(+34%)。2024年实现归母净利润正增长的公司有82家,占比55%,58%(86/149)的公司实现收入正增长。2024年研发费用达704.7亿元,研发费用率减少0.8pp。2024年销售费用达1568.2亿元,销售费用率同比降低约0.2pp。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.